Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1 3 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 32 Colonic Neoplasms 20 Rectal Neoplasms 11 Carcinoma, Hepatocellular 7 Neoplasm Metastasis 5 Stomach Neoplasms 2 Neoplastic Cells, Circulating 2 Neoplasms 2 Liver Neoplasms 2 Recurrence 1 Peritoneal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Oligometastatic Gastric Adenocarcinoma 1 Neuroendocrine Tumors 1 Neoplasms, Second Primary 1 Neoplasm, Residual 1 Neoplasm Recurrence, Local 1 Margins of Excision 1 Locally Advanced Rectal Cancer 1 Gastro-enteropancreatic neuroendocrine tumor 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 73 Fluorouracil 30 Oxaliplatin 20 Leucovorin 20 130-nm albumin-bound paclitaxel 16 Capecitabine 14 Irinotecan 11 Albumin-Bound Paclitaxel 10 irinotecan sucrosofate 8 Radiotherapy 6 Taxes 5 Erlotinib Hydrochloride 5 folfirinox 4 rubitecan 3 Surgical Procedures, Operative 3 Specimen Handling 3 Pancreaticojejunostomy 3 Neoadjuvant Therapy 3 Drug Therapy 3 Cisplatin 3 Chemotherapy, Adjuvant 3 ruxolitinib 2 masitinib 2 dehydroftorafur 2 Saline Solution 2 S 1 (combination) 2 Paclitaxel 2 GV1001 peptide 2 Fentanyl 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Neoplasms × Folfox protocol × Clear all

NCT02923921 2020-10-19

Sequoia

Eli Lilly and Company

Phase 3 Completed

567 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡